Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based healthcare company with two businesses: laboratory services and therapeutic development. Its core operations provide genetic testing, anatomic pathology, and related laboratory interpretation services, while its therapeutic arm is developing cancer drug candidates using a nanoencapsulation and targeted therapy platform.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueGenetic, molecular, and anatomic pathology testing sold on a per-test basis to physicians, institutions, and payors.
Digitized pathology slide review and related technology that supports faster, scalable interpretation.
Technology licensing, CRO-related services, and other revenue tied to pharmaceutical and biotech customers.
Early-stage oncology drug development using a nanoencapsulation and targeted therapy platform.
Customers
Fulgent sells primarily to insurance payors, institutional customers, and individual payors, with laboratory tests purchased on a test-by-test basis rather than under long-term contracts. A small number of customers can represent a large share of revenue, and the company has disclosed significant concentration in one large laboratory customer. Its therapeutic development and BioPharma activities also serve pharmaceutical, biotechnology, and CRO counterparties.
Reimburse genetic and pathology tests; pricing and claims processing drive realized revenue.
Buy outsourced testing capacity and specialized assays when internal capabilities are limited.
Order tests for patient diagnosis and treatment decisions, especially precision diagnostics.
Buy licensing, CRO-related, and other BioPharma services tied to therapeutic development.
Direct consumers or self-pay patients using the company’s testing menu for specific clinical needs.
Strategy
Fulgent is trying to use its scalable testing platform, broad menu, and centralized lab operations to improve margins and win share in precision diagnostics. At the same time, it is building a second growth engine in therapeutic development, aiming to evolve from a diagnostics company into a broader precision medicine platform.
Revenue concentration in one large customer creates volatility and can quickly pressure growth.
Centralized operations and scalable workflows support better unit economics in a price-competitive market.
The company wants to diversify beyond diagnostics and create long-term value in oncology.
Geography
Q3/2024Fulgent is headquartered in the United States and operates CLIA-licensed laboratories in the U.S., which are central to its testing and pathology business. The company also generates non-U.S. revenue, with management citing China, Australia, and Canada as meaningful international markets, and it noted that Puerto Rico and the U.S. Virgin Islands are now grouped with U.S. geographic revenue. International exposure matters because reimbursement, currency, and trade-policy conditions can affect both demand and margins.
Share of the revenue the company reports by geography.
Risks
Fulgent faces customer concentration risk, reimbursement pressure, and regulatory exposure because its testing revenue depends on payor decisions and a limited number of large accounts. It also operates in a heavily regulated laboratory environment with supply-chain dependence on key vendors such as Illumina, while its therapeutic pipeline adds clinical, FDA, and impairment risk typical of early-stage drug development.
- Customer concentrationImpact: HighLikelihood: High
A single large laboratory customer has represented about 22-23% of revenue and may reduce orders.
Exposure: Laboratory services revenue
- Reimbursement and payor riskImpact: HighLikelihood: Medium
Revenue depends on insurance reimbursement rates, claims processing, and payor audits.
Exposure: Diagnostic testing collections
- Regulatory and licensing complianceImpact: HighLikelihood: Medium
Testing operations require ongoing compliance with federal, state, local, and foreign lab rules.
Exposure: Laboratory operations
- Therapeutic development failureImpact: HighLikelihood: Low
Early-stage oncology assets may not prove safe, effective, or commercially viable.
Exposure: R&D and acquired IPR&D
- Supplier concentrationImpact: MediumLikelihood: Medium
The company relies on a limited number of suppliers for reagents and sequencing equipment.
Exposure: Lab throughput and turnaround times
- Cybersecurity and data privacyImpact: MediumLikelihood: Medium
Security incidents could expose sensitive patient data and create liability and reputational damage.
Exposure: Clinical data and lab systems
Accounting
Judgemental itemsTesting revenue is recorded at expected collectible amounts, so reimbursement estimates affect top line and receivables.
Impact: Can change reported revenue and bad-debt expense
Management disclosed increases in provision for credit losses, reflecting collectability risk from payors and customers.
Impact: Affects SG&A and net income
Prior acquisitions have been impaired, and future declines in market value or cash flows could trigger charges.
Impact: Can create large non-cash write-downs
Therapeutic development assets depend on clinical and regulatory success, making fair value highly judgmental.
Impact: Can materially affect balance sheet and future impairment risk
Some therapeutic revenue depends on downstream sales or licensing arrangements, which can be lumpy and timing-sensitive.
Impact: Creates quarter-to-quarter volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Guardant Health, Inc.
GH · Services-Medical Laboratories
Guardant Health is a precision oncology company built around blood- and tissue-based cancer tests, real-world data, and AI analytics.
Pliant Therapeutics, Inc
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Labcorp Holdings Inc
LH · Services-Medical Laboratories
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
NeoGenomics, Inc
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
Last updated: 24/09/2026